‘Dual switch’ that regulates fat formation may harbour obesity cure
April 9th, 2011 - 12:56 pm ICT by ANIWashington, April 09 (ANI): A new study has identified a key regulator of fat cell development that may provide a target for obesity and diabetes drugs.
The scientists at the Scripps Research Institute and collaborating institutions described a protein called TLE3 that acts as a dual switch to turn on signals that stimulate fat cell formation and turn off those that keep fat cells from developing. TLE3 works in partnership with a protein that is already the target of several diabetes drugs, but their use has been plagued by serious side effects.
“There is definitely a need for alternative drug targets,” said Scripps Research Associate Professor Enrique Saez, who led the study with Professor Peter Tontonoz of Howard Hughes Medical Institute and the University of California, Los Angeles (UCLA).
“Our goal is to understand how fat cells form so that we can develop better treatments for obesity and related disorders,” added Saez.
In today’s culture, fat has a bad reputation but it’s not all justified. Adipose (fat) tissue stores excess fatty substances, called lipids, obtained from the diet to prevent them from accumulating in other tissues, such as liver and muscle, where they would cause damage. Fat tissue also produces hormones that help control the balance of insulin in the blood and regulate energy production and consumption.
But in some conditions, such as in obesity, adipose tissue no longer functions as it should.
“When we have too much fat, it tends to become dysfunctional,” said Saez.
“That is when you run into problems like insulin resistance and diabetes,” added Saez.
To find additional players in adipocyte formation, Saez, Tontonoz, and colleagues induced cells growing in a dish to differentiate into adipocytes. The scientists then individually tested the ability of 18,000 genes to augment the conversion of undifferentiated cells into fully functioning adipocytes, looking for genes that might play a role in this process.
In this way, they identified the gene encoding the TLE3 protein, which had never before been linked to fat development.
Saez, Tontonoz, and colleagues discovered that PPAR? turns on the production of TLE3. TLE3 then forms a complex with PPAR? and helps it turn on other genes and pathways needed for adipocyte formation.
In addition, TLE3 turns off Wnt signaling.
“This is how Wnt gets shut off to allow differentiation to occur,” said Saez.
“TLE3 has a dual function: it is a positive regulator for PPAR? and a negative regulator for Wnt,” added Saez.
The study is detailed in the latest issue of Cell Metabolism. (ANI)
- Why a class of diabetes drugs boosts weight gain - May 02, 2011
- Link between obesity, insulin resistance paves way for safer diabetes drugs - Jul 22, 2010
- Protein that modulates metabolic dysfunction in obesity identified - Jun 18, 2010
- Molecular 'switch' that contributes to cellular aging process identified - Dec 01, 2010
- Here's what causes the birth of a fat cell - Aug 17, 2010
- Potential new target for diabetes, heart disease treatments identified - Nov 17, 2010
- Changes in fat cells linked to diabetes - Jul 07, 2010
- Link between high-fat diets, type 2 diabetes clarified - Apr 12, 2011
- Our body clocks determine how much fat we burn - Nov 16, 2010
- Micro-RNA that regulates insulin in obesity identified - Apr 01, 2011
- Cells coordinate to promote exercise - Sep 20, 2011
- Scientists discover novel anti-diabetes mechanism - Jul 22, 2010
- Genetic discovery could pave way for obesity, diabetes treatments - Aug 27, 2009
- Histone 'map' yields key insights into fat cell formation - Oct 01, 2010
- Blueberries could help fight the flab - Apr 11, 2011
Tags: bad reputation, cell formation, diabetes drugs, drug targets, dual switch, fat cell, fat cells, fatty substances, howard hughes medical, howard hughes medical institute, hughes medical institute, insulin resistance, obesity cure, professor peter, research associate professor, saez, scripps research institute, target, undifferentiated cells, university of california los angeles